



DEFENSE
HEALTH AGENCY

MB&RO

**OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
HEALTH AFFAIRS
16401 EAST CENTRETECH PARKWAY
AURORA, CO 80011-9066**

**CHANGE 112
6010.57-M
MAY 20, 2014**

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL
FOR
TRICARE POLICY MANUAL (TPM), FEBRUARY 2008**

The TRICARE Management Activity has authorized the following addition(s)/revision(s).

CHANGE TITLE: EVOLVING PRACTICE 14-002

CONREQ: 16929

PAGE CHANGE(S): See page 2.

SUMMARY OF CHANGE(S): See page 3.

EFFECTIVE DATE: See page 3.

IMPLEMENTATION DATE: June 18, 2014.

**FAZZINI.ANN.
NOREEN.119
9802271**

Digitally signed by
FAZZINI,ANN.NOREEN.1199802271
DN: c=US, o=U.S. Government,
ou=DoD, ou=PKI, ou=TMA,
cn=FAZZINI.ANN.NOREEN.1199802
271
Date: 2014.05.13 13:06:23 -06'00'

**Ann N. Fazzini
Team Chief, Medical Benefits &
Reimbursement Office (MB&RO)
Defense Health Agency (DHA)**

**ATTACHMENT(S): 35 PAGE(S)
DISTRIBUTION: 6010.57-M**

WHEN PRESCRIBED ACTION HAS BEEN TAKEN, FILE THIS TRANSMITTAL WITH BASIC DOCUMENT.

**CHANGE 112
6010.57-M
MAY 20, 2014**

REMOVE PAGE(S)

CHAPTER 4

Section 9.1, pages 5 and 6

Section 17.1, pages 1 and 2

Section 23.1, pages 7 through 10

APPENDIX A

pages 5 through 33

INSERT PAGE(S)

Section 9.1, pages 5 and 6

Section 17.1, pages 1 and 2

Section 23.1, pages 7 through 10

pages 5 through 33

SUMMARY OF CHANGES

CHAPTER 4

1. Section 9.1. This change confirms that Transcatheter Aortic Valve Replacement (TAVR) for the treatment of symptomatic severe aortic stenosis is proven safe and effective for patients who are not candidates for Surgical Aortic Valve Replacement (SAVR). EFFECTIVE DATE: 02/08/2012
2. Section 17.1. This change confirms that sufficient reliable evidence does not exist to support the determination that percutaneous transcatheter embolization of ovarian and/or internal iliac veins for the treatment of Pelvic Congestion Syndrome (PCS) is safe and effective. It is recommended that it be considered unproven and excluded from coverage. EFFECTIVE DATE: N/A
3. Section 23.1. This change confirms that non-myleloablative allogeneic hematopoietic stem-cell transplantation for Crohn's disease is considered unproven. EFFECTIVE DATE: N/A

